

In particular, the present invention relates to the following modified kringle 5 peptides: NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 17); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 18); Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 20); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub> (SEQ ID: NO 21); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 23); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 24); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 26); MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 27); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 28); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 29); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 30); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 31); MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 32); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 33); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 36); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 37); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 38); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 39); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA-MPA)-NH<sub>2</sub> (SEQ ID NO: 40); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA<sub>n</sub>-MPA)-NH<sub>2</sub> (SEQ ID NO: 41); and other modified kringle 5 peptides.

Please replace the paragraph beginning at page 40, line 1, with the following rewritten paragraph:

**Example 1**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 42)**

Please replace the paragraph beginning at page 40, line 15, with the following rewritten paragraph:

**Example 2**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 43)**

Please replace the paragraph beginning at page 40, line 29, with the following rewritten paragraph:

**Example 3**

**Preparation of Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 44)**

Please replace the paragraph beginning at page 41, line 14, with the following rewritten paragraph:

**Example 4**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.4TFA (SEQ ID NO: 45)**

Please replace the paragraph beginning at page 42, line 2, with the following rewritten paragraph:

**Example 5**

A 7 Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub>.2TFA (SEQ ID NO: 46) --

Please replace the paragraph beginning at page 42, line 18, with the following rewritten paragraph:

**Example 6**

A 8 Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 47) --

Please replace the paragraph beginning at page 43, line 16, with the following rewritten paragraph:

**Example 7**

A 9 Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 48) --

Please replace the paragraph beginning at page 44, line 13, with the following rewritten paragraph:

**Example 8**

A 10 Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 49) --

Please replace the paragraph beginning at page 45, line 7, with the following rewritten paragraph:

**Example 9**

A<sup>11</sup> Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 50) --

Please replace the paragraph beginning at page 46, line 4, with the following rewritten paragraph:

**Example 10**

A<sup>12</sup> Preparation of (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 51) --

Please replace the paragraph beginning at page 47, line 3, with the following rewritten paragraph:

**Example 11**

A<sup>13</sup> Preparation of (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 52) --

Please replace the paragraph beginning at page 48, line 1, with the following rewritten paragraph:

**Example 12**

A<sup>14</sup> Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>.3TFA (SEQ ID NO: 53) --

Please replace the paragraph beginning at page 49, line 4, with the following rewritten paragraph:

**Example 13**

A<sup>15</sup> Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 54) --

Please replace the paragraph beginning at page 50, line 7, with the following rewritten paragraph:

**Example 14**

A<sup>16</sup> Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 55) --

Please replace the paragraph beginning at page 51, line 6, with the following rewritten paragraph:

**Example 15**

A<sup>17</sup> Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>.TFA (SEQ ID NO: 56) --

Please replace the paragraph beginning at page 52, line 4, with the following rewritten paragraph:

**Example 16**

A<sup>18</sup> Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 57) --

Please replace the paragraph beginning at page 53, line 2, with the following rewritten paragraph:

**Example 17**

**Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 58)**

Please replace the paragraph beginning at page 54, line 1, with the following rewritten paragraph:

**Example 18**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 59)**

Please replace the paragraph beginning at page 54, line 30, with the following rewritten paragraph:

**Example 19**

**Preparation of (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 60)**

Please replace the paragraph beginning at page 55, line 26, with the following rewritten paragraph:

**Example 20**

**Preparation of (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 61)**

Please replace the paragraph beginning at page 56, line 20, with the following rewritten paragraph:

**Example 21**

A<sup>23</sup> Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 62) --

Please replace the paragraph beginning at page 57; line 17, with the following rewritten paragraph:

**Example 22**

A<sup>24</sup> Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 63) --

Please replace the paragraph beginning at page 58, line 13, with the following rewritten paragraph:

**Example 23**

A<sup>25</sup> Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 64) --

Please replace the paragraph beginning at page 59, line 7, with the following rewritten paragraph:

**Example 24**

A<sup>26</sup> Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 65) --